[Trastuzumab and Fcgamma].
Trastuzumab is a recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2(HER2). ADCC is considered to be a major mechanism of anti-tumor effect of trastuzumab. The difference in subtype and gene polymorphism of Fcgamma receptor of effecter cells causes difference in affinity to Fc fragment of antibody and in ADCC activity. Consequently, it may cause the difference of trastuzumab treatment efficacy. These findings suggest the importance of gene polymorphism in strategy of new therapeutic antibody development and predict of treatment efficacy.
Yamashiro
Hiroyasu
H
Dept. of Surgery, Graduate School of Medicine, Kyoto University, Kyoro, Japan.
Toi
Masakazu
M
D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000276:immunology*; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D050260:Carbohydrate Metabolism; D000068818:Cetuximab; D006801:Humans; D011110:Polymorphism, Genetic / Q000235:genetics; D017452:Receptors, IgG / Q000235:genetics / Q000276:immunology*; D000069283:Rituximab; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D017452:Receptors, IgG; D000069283:Rituximab; D000068878:Trastuzumab; D000068818:Cetuximab